# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average b	urden
nours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)  1. Name and Address of Reporting Person * MATHER CHARLES E IV  (Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306  (Street)  NEW YORK, NY 10022			2. Issuer Name <b>and</b> Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]					ון	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
			S HOLDING	3. Date of Earliest Transaction (Month/Day/Year) 02/09/2016						Officer (give title below) Other (specify below)				ow)	
			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  X_ Form filed by One Reporting Person  Form filed by More than One Reporting Person				Line)		
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu					es Acquirec	L ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea			Date, i	(Instr. 8		(A) or Disposed		Reported Ti		Owned Following ransaction(s)		Ownership Form:	Beneficial
				(Month/Day	// y eai		ode	V Amo	ount (A) or (D)	l l	Instr. 3 and 4)  Direct (D) Owned (Instr. (I) (Instr. 4)		Ownership (Instr. 4)		
Reminder: R				Derivative S				contained form disp ed, Dispose	d in this foo plays a cur ed of, or Ber	orm are no rrently val	ot require lid OMB		ond unless		1474 (9-02)
1. Title of	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Yea	3A. Deemed Execution Date	e.g., puts, ca 4. Transac Code	tion (	5. Numof Derivat Securiti Acquire (A) or	ber (alive (ies	contained form disp ed, Dispose	d in this foolays a cui d of, or Benertible securcisable ion Date	orm are no rrently val	ot require lid OMB of Owned	ed to respondent of the second	9. Number of Derivatives Beneficially Owned Following	f 10. Ownersl Form of Derivati Security Direct (1	11. Naturip of Indire Benefici Owners! (Instr. 4
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date r) any	e.g., puts, ca 4. Transac Code	tion ()	varrant 5. Num of Derivat Securiti Acquire	ber (alies ed	contained form disp ed, Dispose otions, conv 6. Date Exe and Expirat	d in this foolays a cui d of, or Benertible securcisable ion Date	rently value of rently value of rently value of rently value of rently of re	ot require lid OMB of Owned	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	of 10. Ownersl Form of Derivati Security Direct (1 or Indire	11. Nature of Indire seneration of Owners! (Instr. 4) ot
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date r) any	e.g., puts, ca 4. Transac Code	tion ()	varrant 5. Num of Derivat Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5)	ber (ive (ies ed ed ed s, 4,	contained form disp ed, Dispose otions, conv 6. Date Exe and Expirat	d in this follows a cuited of, or Berertible securicisable ion Date 1/Year)	rently value (ineficially Curities)  7. Title an Amount o Underlyin Securities (Instr. 3 an	ot require lid OMB of Owned	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions	of 10. Ownersl Form of Derivati Security Direct (I or Indirects) (I)	11. Natural of Indirection of Indire

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
MATHER CHARLES E IV C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022	X				

### **Signatures**

/s/Jessica Morris, Attorney-in-Fact	02/10/2016
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- (2) These restricted stock units are scheduled to vest 100% on February 9, 2017.
- (3) The restricted stock units were granted pursuant to the Issuer's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.